-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On January 10, the State Food and Drug Administration announced that it has recently approved the listing of 1.
2 innovative drug icariin soft capsules through the priority review and approval process
.
2 innovative drug icariin soft capsules through the priority review and approval process
.
The drug is used for unresectable hepatocellular carcinoma that isnot suitable for or the patient refuses to receive standard treatment and has not received systemic systemic therapy before, and the patient's peripheral blood composite markers meet at least two of the following detection indicators: AFP≥400 ng /mL; TNF-α<2.
5 pg/mL; IFN-γ≥7.
0 pg/mL
.
The launch of this variety provides a new treatment option for patients with hepatocellular carcinoma
.
The holder of the drug marketing authorization is Beijing Shennuoji Pharmaceutical Technology Co.
,
Ltd.
5 pg/mL; IFN-γ≥7.
0 pg/mL
.
The launch of this variety provides a new treatment option for patients with hepatocellular carcinoma
.
The holder of the drug marketing authorization is Beijing Shennuoji Pharmaceutical Technology Co.
,
Ltd.
The State Food and Drug Administration requires the holder of the marketing authorization of this variety to continue to complete the relevant post-marketing research work in accordance with the attached conditions and requirements
.
.
On January 10, the State Food and Drug Administration announced that it has recently approved the listing of 1.
2 innovative drug icariin soft capsules through the priority review and approval process
.
2 innovative drug icariin soft capsules through the priority review and approval process
.
The drug is used for unresectable hepatocellular carcinoma that is not suitable for or the patient refuses to receive standard treatment and has not received systemic systemic therapy before, and the patient's peripheral blood composite markers meet at least two of the following detection indicators: AFP≥400 ng /mL; TNF-α<2.
5 pg/mL; IFN-γ≥7.
0 pg/mL
.
The launch of this variety provides a new treatment option for patients with hepatocellular carcinoma
.
The holder of the drug marketing authorization is Beijing Shennuoji Pharmaceutical Technology Co.
,
Ltd.
5 pg/mL; IFN-γ≥7.
0 pg/mL
.
The launch of this variety provides a new treatment option for patients with hepatocellular carcinoma
.
The holder of the drug marketing authorization is Beijing Shennuoji Pharmaceutical Technology Co.
,
Ltd.
The State Food and Drug Administration requires the holder of the marketing authorization of this variety to continue to complete the relevant post-marketing research work in accordance with the attached conditions and requirements
.
.
On January 10, the State Food and Drug Administration announced that it has recently approved the listing of 1.
2 innovative drug icariin soft capsules through the priority review and approval process
.
2 innovative drug icariin soft capsules through the priority review and approval process
.
The drug is used for unresectable hepatocellular carcinoma that is not suitable for or the patient refuses to receive standard treatment and has not received systemic systemic therapy before, and the patient's peripheral blood composite markers meet at least two of the following detection indicators: AFP≥400 ng /mL; TNF-α<2.
5 pg/mL; IFN-γ≥7.
0 pg/mL
.
The launch of this variety provides a new treatment option for patients with hepatocellular carcinoma
.
The holder of the drug marketing authorization is Beijing Shennuoji Pharmaceutical Technology Co.
,
Ltd.
Standard standard standard medicine medicine medicine medicine medicine medicine5 pg/mL; IFN-γ≥7.
0 pg/mL
.
The launch of this variety provides a new treatment option for patients with hepatocellular carcinoma
.
The holder of the drug marketing authorization is Beijing Shennuoji Pharmaceutical Technology Co.
,
Ltd.
The State Food and Drug Administration requires the holder of the marketing authorization of this variety to continue to complete the relevant post-marketing research work in accordance with the attached conditions and requirements
.
.
